Evidence-Based Complementary and Alternative Medicine / 2014 / Article / Tab 1 / Research Article
Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial Group
values HxA (
) Control (
) Age in years (mean ± SD;
-test)
0.228 Tumor status (
; Chi square test) Tumor classification 0.619 T1 9 9 T2 24 19 T3 1 2 T
0 1 Pos. lymph nodes 0.849 N0 16 16 N1 16 14 N2 2 1 Tumor grade 0.474 G1 3 1 G2 28 24 G3 3 6 Menopause status (
; Kruskal-Wallis test) 0.475 Premenopausal 18 13 Perimenopausal 2 1 Postmenopausal 13 17 Unknown 1 0 Receptor status estrogen 0.507 Positive 21 17 Negative 9 12 unknown 4 2 Receptor status progesterone 0.620 Positive 22 19 Negative 8 10 Unknown 4 2 Body Mass Index (mean ± SD;
-test)
0.709 Karnofsky-Index (mean ± SD)
— Abnormal findings on physical examination (
) 0 0 — Vital signs (mean ± SD;
-test) Blood pressure systolic (mmHg)
0.139 Blood pressure diastolic (mmHg)
0.209 Pulse (/min)
0.945 Temperature (°C)
1.000 Primary outcomes EORTC QLQ-C30 (mean ± SD; Mann-Whitney
-test) Global health status
0.713 Physical functioning
0.872 Role functioning
0.443 Emotional functioning
0.274 Cognitive functioning
0.23 Social functioning
0.226 Fatigue
0.894 Nausea and vomiting
0.285 Pain
0.273 Dyspnea
0.839 Insomnia
0.902 Appetite loss
0.704 Constipation
0.914 Diarrhoea
0.498 Financial difficulties
0.661 Secondary outcomes Incidence of neutropenia 0 0 —